{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:04:24Z","timestamp":1771909464211,"version":"3.50.1"},"reference-count":0,"publisher":"AVES YAYINCILIK A.\u015e.","issue":"2","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Turkish Journal of Gastroenterology"],"abstract":"<jats:p>Background: Rat sarcoma virus mutational status guides first-line treatment in metastatic colorectal cancer. This study was a multicenter, multi-country ambispective, observational study in the Middle East and North Africa assessing regional rat sarcoma virus testing practices in newly diagnosed patients.\n\nMethods: The retrospective arm (2011-2014) included adults with metastatic colorectal cancer who had initiated first-line therapy with \u22651 post-baseline visit and survival data. The prospective arm (2014-2019) enrolled newly diagnosed patients with histologically proven metastatic colorectal cancer with \u22651 measurable lesion per Response Evaluation Criteria in Solid Tumors, and tissue availability for biomarker analysis. Data look-back and follow-up were 2 years; the rate of RAS mutation was evaluated.\n\nResults: RAS testing was ordered for patients in retrospective (326\/417) and prospective (407\/500) studies. In the former, testing was typically prescribed after first-line treatment initiation, significantly more in patients with stage IV disease (P &lt; .005), resulting in the addition of targeted therapy (41.8% anti-epidermal growth factor receptor, 30.2% anti-vascular endothelial growth factor) in wild-type metastatic colorectal cancer, and significantly impacted the treatment of left-sided tumors (P = .037). In the latter, 58.4% were RAS wild-type; 41.6% were RAS mutant. Non-prescription of RAS testing was attributed to test unavailability, financial, or medical reasons; predictors of testing prescription were older age, primary tumor in ascending colon, and high tumor grade. RAS status knowledge resulted in the addition of anti-vascular endothelial growth factor (20.4%) or anti-epidermal growth factor receptor therapy (21.2%).\n\nConclusion: Before 2014, RAS testing in patients with colorectal cancer in the Middle East and North Africa was often performed after first-line treatment. Testing is more routine in newly diagnosed patients, potentially shifting early treatment patterns\n\nCite this article as: Oukkal M, Bouzid K, Bounedjar A, et al. Middle East and North Africa registry to characterize rate of RAS testing status in newly diagnosed patients with metastatic colorectal cancer. Turk J Gastroenterol. 2023;34(2):118-127.<\/jats:p>","DOI":"10.5152\/tjg.2022.22106","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T07:10:31Z","timestamp":1669619431000},"page":"118-127","source":"Crossref","is-referenced-by-count":3,"title":["Middle East and North Africa Registry to Characterize Rate  of RAS Testing Status in Newly Diagnosed Patients with  Metastatic Colorectal Cancer"],"prefix":"10.5152","volume":"34","author":[{"given":"Mohammed","family":"Oukkal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamel","family":"Bouzid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adda","family":"Bounedjar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulsalam","family":"Alnajar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fouad Abou","family":"Taleb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Alsharm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassen","family":"Mahfouf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blaha","family":"Larbaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr","family":"Abdelaziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assia","family":"Ouamer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linah","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3111","published-online":{"date-parts":[[2022,11,24]]},"container-title":["Turkish Journal of Gastroenterology"],"original-title":[],"link":[{"URL":"http:\/\/turkjgastroenterol.org\/index.php\/tjg\/article\/download\/4603\/4290","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T02:35:36Z","timestamp":1771900536000},"score":1,"resource":{"primary":{"URL":"http:\/\/turkjgastroenterol.org\/index.php\/tjg\/article\/view\/4603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,23]]}},"URL":"https:\/\/doi.org\/10.5152\/tjg.2022.22106","relation":{},"ISSN":["2148-5607"],"issn-type":[{"value":"2148-5607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,24]]}}}